Guggenheim Capital’s Sophiris Bio, Inc. SPHS Stock Holding History

Guggenheim Capital’s Portfolio SPHS Stock Details SPHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,975	Closed	-$23K	–	2937
2017 Q3	$23K	Buy	+10,975	New	+$22.7K	﹤0.01%	2743

Other funds holding SPHS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Guggenheim Capital's SPHS Position: Q4 2017 in Review

Guggenheim Capital sold out of Sophiris Bio, Inc. (SPHS) in Q4 2017, closing a stake of 10,975 shares — an estimated $23K sold.

Guggenheim Capital first reported a position in SPHS in Q3 2017 and held it in 1 quarter. The position peaked at $23K in Q3 2017. 32 funds tracked by Wall St. Rank hold SPHS as of Q4 2017.

Guggenheim Capital reported no remaining Sophiris Bio, Inc. position as of Q4 2017 after selling out during the quarter.
Guggenheim Capital sold 10,975 Sophiris Bio, Inc. shares in Q4 2017, an estimated $23K.
Guggenheim Capital first reported a position in Sophiris Bio, Inc. in Q3 2017 and held it in 1 quarter.
Guggenheim Capital's Sophiris Bio, Inc. position peaked at $23K in Q3 2017.
32 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q4 2017.

Based on Guggenheim Capital's 13F filing for Q4 2017, filed 14 Feb 2018.